Navigation Links
Ebola virus disarmed by excising a single gene
Date:1/21/2008

MADISON - The deadly Ebola virus, an emerging public health concern in Africa and a potential biological weapon, ranks among the most feared of exotic pathogens.

Due to its virulent nature, and because no vaccines or treatments are available, scientists studying the agent have had to work under the most stringent biocontainment protocols, limiting research to a few highly specialized labs and hampering the ability of scientists to develop countermeasures.

Now, however, a team of researchers from the University of Wisconsin-Madison has figured out a way to genetically disarm the virus, effectively confining it to a set of specialized cells and making the agent safe to study under conditions far less stringent than those currently imposed.

"We wanted to make biologically contained Ebola virus," explains Yoshihiro Kawaoka, a professor of pathobiological sciences in the UW-Madison School of Veterinary Medicine and the senior author of a paper describing the system for containing the virus published today (Jan. 21, 2008) in the Proceedings of the National Academy of Sciences. "This is a great system."

The Ebola virus first emerged in 1976 with outbreaks in Sudan and Zaire. There are several strains of the virus, which causes hemorrhagic fever and during outbreaks kills anywhere from 50-90 percent of its human victims.

At present, research on live Ebola virus is confined to the very highest level of biosafety, known as Biosafety Level 4 (BSL 4). Because such laboratories are rare, small and very expensive, basic research that is the basis for any potential drugs or vaccines to thwart the virus has been limited to perhaps half a dozen labs worldwide. The system devised by Kawaoka and his colleagues could provide a way to greatly expand studies of the pathogen and speed the development of countermeasures.

Taming Ebola virus, according to the new study, depends on a single gene known as VP30. Like most viruses, Ebo
'/>"/>

Contact: Yoshihiro Kawaoka
kawaokay@svm.vetmed.wisc.edu
608-265-4925
University of Wisconsin-Madison
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Features of replication suggest viruses have common themes, vulnerabilities
2. First all-African GM crop is resistant to maize streak virus
3. Carnegie Mellon scientist uses mass spectrometer to weigh virus particle, von Willebrand factor
4. Gamma globulin effective in treating eye infections caused by adenoviruses
5. Discovery may help defang viruses
6. Who will recover spontaneously from hepatitis C virus infection
7. Prions and retroviruses -- an unholy alliance?
8. Scientists learn structure of enzyme in unusual virus
9. UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC
10. New field-deployable biosensor detects avian influenza virus in minutes instead of days
11. Depression, aging, and proteins made by a virus may all play role in heart disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD ), a ... market, issues the following corporate shareholder update following the ... Letter from the CEO : ... joined the NASDAQ to support ramping of production of ... authentication products and services. This strategic achievement positions NXT-ID to ...
(Date:9/21/2014)... (black-eyed peas) is a fascinating example of how science ... the story of the scientist behind the research. ... the 21st Century to serve as an accessible summary ... recently published by the Crop Science Society of America, ... , Singh has devoted his life,s work to solving ...
(Date:9/21/2014)... immune T cells may have the ability to trigger ... study led by King,s College London. Although their immune ... may still be able to mount a strong immune ... Nature Medicine . , Our immune system is made ... neutrophils which play an important role in the frontline ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Immune system of newborn babies is stronger than previously thought 2
... release is available in German . ... travel of tomorrow is meant to become quieter, cleaner and ... to accomplish just that as part of the EU ... technical aspects of air travel to the test, evaluating and ...
... study has highlighted the sensitivity of Australia,s species and ... ways of thinking about biodiversity conservation. ,Climate change ... natural landscapes by 2030, lead researcher, CSIRO,s Dr Michael ... be very significant and widespread. Many of the environments ...
... a leading software company in the clinical ... Next Generation Biobanking software platform for biomarker-based ... and academic research centers involved in biomarker-based ... effectively conduct externalized, science-driven collaborative studies. ...
Cached Biology News:Fraunhofer supports continuation of 'Clean Sky' program 2Major changes needed to protect Australia's species and ecosystems 2BioFortis Inc., Introduces Next Generation Biobanking Software Platform for Biomarker-Based Clinical Research 2
(Date:9/22/2014)... University of Manchester have generated a new star-shaped molecule made ... its kind ever created. , Known as a ... one for over a quarter of a century and the ... . , Consisting of two molecular triangles, entwined about ... molecules are tiny each triangle is 114 atoms in ...
(Date:9/22/2014)... , Sept. 22, 2014 US demand to ... for specialty biocides is forecast to rise 3.9 percent ... terms, demand is projected to increase 1.3 percent per ... A strong rebound in construction expenditures will support demand ... coatings markets, while growth in consumer spending and manufacturing ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Invisible ... diagnostics for the food and beverage industries, announced ... be distributed under a non-exclusive agreement by Enartis, ... services. , Enartis, an Esseco Group company headquartered ... winemakers in California and other global markets for ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... ST. LOUIS, Oct. 2 /PRNewswire-FirstCall/ -- ... ) has elected Dr. George M. Church as a Director ... Professor of Genetics at the Harvard Medical School and Director ... Dr. Church pioneered technology innovations early in the development of ...
... Host Conference Call-- , CALGARY, Oct. 2 /PRNewswire-FirstCall/ - ... it has reached an agreement with the U.S. Food ... (SPA) process for the design of a Phase 3 ... in patients with platinum-refractory head and neck cancers. The ...
... ... the recipients of the 2009 Orange County Emerging Growth Awards, recognizing companies headquartered in ... significant growth over the last 12 months and that have made a positive impact ... ...
Cached Biology Technology:Sigma-Aldrich Elects George M. Church as Director 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 2Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 3Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 4
Takara's Mutan-Super Express Km Kit is designed to achieve site-directed mutagenesis in just one day. It is based on Oligonucleotide-directed Dual Amber (ODA) method, using the advantages of LA (Long...
... 4 deuterium atoms at the 9, 10, 12, ... as an internal standard for the quantification of ... produced by incubation of linoleic acid with plant ... inhibit the adhesion of tumor cells to the ...
... and TriEx Insect Cell Medium are recommended ... This cell/medium combination has been selected based ... protein expression levels observed specifically with baculoviruses ... that our Ready-Plaque Sf9 Cells and BacVector ...
...
Biology Products: